Novel agents in the treatment of hodgkin lymphoma: biological basis and clinical results

Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. The prognosis for patients who relapse, or have evidence for refractory disease, however is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research